Consensus Amneal Pharmaceuticals, Inc.

Equities

AMRX

US03168L1052

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
5.36 ^USD	-1.83%		-5.80%	-11.70%

Apr. 18	Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US	MT
Apr. 18	Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll	CI

Evolution of the average Target Price on Amneal Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

61.gRFsgcGQt3b-w8f16WYkpv_QAE80eq6Fp4W1G-bj4OI.7mZbt6D9zRWuuayznj5XkbePSGJGSuHq1PTgdJSnqNWxegDDqebFDM3xoA~ae833db232e187615953c702be6e756e

Analyst Recommendations on Amneal Pharmaceuticals, Inc.

Goldman Sachs Adjusts Price Target on Amneal Pharmaceuticals to $6.25 From $5.50, Maintains Buy Rating	Mar. 04	MT
Barclays Adjusts Price Target on Amneal Pharmaceuticals to $8 From $6, Maintains Overweight Rating	Jan. 29	MT
Truist Adjusts Amneal Pharmaceuticals' Price Target to $6 From $4, Keeps Buy Rating	23-08-07	MT
Barclays Adjusts Price Target on Amneal Pharmaceuticals to $5 From $4, Maintains Overweight Rating	23-08-07	MT
Piper Sandler Adjusts Amneal Pharmaceuticals' Price Target to $3 From $5, Keeps Overweight Rating	23-05-08	MT
Truist Securities Trims Amneal Pharmaceuticals' Price Target to $4 From $5, Maintains Buy Rating	23-03-28	MT
Barclays Adjusts Price Target on Amneal Pharmaceuticals to $4 From $7, Keeps Overweight Rating	23-03-10	MT
Goldman Sachs Adjusts Price Target on Amneal Pharmaceuticals to $3 From $3.50, Maintains Buy Rating	23-03-03	MT
BMO Capital Adjusts Price Target on Amneal Pharmaceuticals to $4 From $5, Maintains Market Perform Rating	23-03-03	MT
Goldman Sachs Trims Amneal Pharmaceuticals Price Target to $4 From $4.50, Maintains Buy Rating	22-08-08	MT
Truist Securities Trims Amneal Pharmaceuticals' Price Target to $6 From $7, Maintains Buy Rating	22-08-01	MT
Goldman Sachs Adjusts Amneal Pharmaceuticals Price Target to $4.50 From $6, Maintains Buy Rating	22-05-12	MT
Amneal Pharmaceuticals : Moody's Upgrades Amneal Pharmaceuticals Ratings One Notch to B2; Outlook Stable	21-10-13	MT
AMNEAL PHARMACEUTICALS : Guggenheim Adjusts Amneal Pharmaceuticals' Price Target to $8 From $6.50, Maintains Buy Rating	21-04-14	MT
AMNEAL PHARMACEUTICALS : Goldman Sachs Upgrades Amneal Pharmaceuticals to Buy From Sell, Adjusts Price Target to $6.50 From $4	21-03-08	MT
AMNEAL PHARMACEUTICALS : Barclays Adjusts Amneal Pharmaceuticals PT to $8 From $6, Maintains Overweight Rating	21-03-01	MT
AMNEAL PHARMACEUTICALS : RBC Capital Adjusts Price Target on Amneal Pharmaceuticals to $5 From $4, Keeps Sector Perform Rating	21-03-01	MT
AMNEAL PHARMACEUTICALS : Morgan Stanley Adjusts PT on Amneal Pharmaceuticals to $5 From $3, Citing 'Ability to Deliver on Cost Efficiencies,' Margin Expansion; Equal-Weight Rating Kept	20-12-21	MT
AMNEAL PHARMACEUTICALS : Barclays Upgrades Amneal Pharmaceuticals to Overweight From Equal-Weight; Price Target is $6	20-12-14	MT
AMNEAL PHARMACEUTICALS : Guggenheim Upgrades Amneal Pharmaceuticals to Buy From Neutral; Price Target is $5.50	20-12-14	MT